Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Buys Clearstone Central Laboratories

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – In a deal that will strengthen Laboratory Corporation of America's companion diagnostics business, the company today announced a definitive agreement to purchase central laboratory service provider Clearstone Central Laboratories.

LabCorp said the deal will provide it with a global network of central laboratories and Clearstone's clinical trials management system Apollo CLPM, which provides real-time access to global data, strengthened chain of custody, automated sample stability monitoring, and guaranteed consistency across all lab sites.

In a statement, David King, chairman and CEO of LabCorp, added that the acquisition will extend "our global footprint and service capabilities in key geographies in Asia Pacific, and advances the company's companion diagnostics and personalized medicine strategy."

Based in Toronto, Clearstone provides central laboratory services for late-stage clinical trials.

LabCorp said that upon completion of the deal, the merged company will have the largest available biomarker assay portfolio "with globally harmonized and state-of-the-art testing platforms in areas, such as pharmacogenomics, microbiology, immunohistochemistry, allergy testing, cytogenetics, and flow cytometry."

The deal is expected to close in the second quarter. Financial and other terms were not disclosed.

The deal is the second by LabCorp this year. It currently is awaiting US regulatory approval for its proposed $85.4 million purchase of Orchid Cellmark. In September, it also acquired Genzyme Genetics for $925 million.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.